San Diego-based Sherpa Clinical Packaging has been acquired by PCI Pharma Services under a deal announced Sept. 11 in which terms were not disclosed.
With facilities that include cold chain technologies, Sherpa specializes in clinical trial services, such as packaging, labeling, distribution, storage, and returns and destruction. The company has 50 employees.
“With this acquisition, our customers will now have access to PCI’s expanded clinical packaging services, extensive manufacturing of clinical trial materials, as well as global reach through U.S., European, and Asia Pacific depots to support their clinical studies,” said Mark Paiz, president of Sherpa.
He will stay on in the near-term to "ensure a smooth transition of operations," said a company spokeswoman in an email.
PCI Pharma, headquarted in Pennsylvania, is in the business of “molecule-to-market service,” spanning contract development, manufacturing, clinical supply and commercial packaging. The company is expanding its global clinical services business, with Sherpa being its third acquisition in a year.
Mark Shepanski, Sherpa's senior director of quality, will become the site leader, according to the company.
This story was updated to include Sherpa's employee count and what's next for Paiz and Shepanski.